Fda Ok's Odomzo from Novartis for common skin cancer type

A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin’s top layer, has won Food and Drug Administration approval. Odomzo was approved for patients whose cancer hasn’t spread to other body parts, but recurred after surgery or radiation therapy or can’t be cured by those treatments.